Amgen Inc. reported that third-quarter 2020 adjusted profit rose 17% due to stronger sales of drugs such as the osteoporosis treatment Prolia and the psoriasis medication Otezla, bucking challenges from lower drug prices and Covid-19.
If you are not happy with the results below please do another search
50 search results for:
Regeneron Pharmaceuticals Inc.’s coronavirus antibody cocktail – the experimental treatment that U.S. President Donald Trump received – significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate Covid-19.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes the use of miniature lungs and colons to help test Covid-19 treatments.
A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
UW Health University Hospital in Madison, Wisconsin has been rushing to convert available space into units for Covid-19 patients, as the state’s medical facilities struggle to keep pace with a surge in new infections.
A new study suggests that some patients could see a decline in cognition that is equivalent to the brain aging approximately 10 years.
The U.S. Food and Drug Administration approved Kala Pharmaceuticals’ Eysuvis for the short-term treatment of dry eye disease.
Swiss pharma giant Novartis AG is harnessing the power of Zurich-based Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat Covid-19 infection.
Pfizer indicated that the company’s Phase III clinical trial of 44,000 volunteers with partner BioNTech needed less than 2,000 people to be fully enrolled.